Leukocyte Adhesion Deficiency

The FDA has designated Fast Track status to Cerecor Inc's (NASDAQ: CERC) CERC-803 for the treatment of Leukocyte Adhesion Deficiency Type 2 (LAD-II), a rare congenital disorder due to mutations in the SLC35C1 gene, and characterized by frequent infections, persistent...